TS-005782 — This new IP introduces a modular, cell‑derived lipid nanoparticle (LNP) delivery platform engineered for highly efficient, biocompatible, and customizable delivery of nucleic acids and therapeutic agents, which is a significant improvement over existing synthetic LNP technologies.

TS-005781 — This invention introduces an advanced mRNA‑based gene‑therapy platform designed to treat both genetic and acquired elastin‑deficiency conditions, including autosomal dominant cutis laxa (ADCL), supravalvular aortic stenosis (SVAS), emphysema, aneurysms, and age‑related tissue degeneration. This IP represents a significant advancement over both plasmid‑based and existing mRNA therapies, establishing a safer, more effective strategy to address the root cause of elastin‑related diseases.

TS-004705 — Modified GNPs offer a promising avenue for therapeutic interventions in the field of rare neurological disorders, providing insights into their effectiveness at the cellular level and offering potential avenues for clinical applications.